Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarPrivate Magnificent 7Emerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary marketplace / Explore private companies / 4D Molecular Therapeutics (4DMT) IPO
4D Molecular Therapeutics (4DMT)

4D Molecular Therapeutics (4DMT) IPO

Register for details
For more details on financing and valuation of private companies similar to 4D Molecular Therapeutics (4DMT) before its IPO, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

4D Molecular Therapeutics (4DMT) IPO date and status

2013
Founded
Dec 2020
IPO Completed

Company details

4DMT is a biotechnology company focused on pioneering the development of precision gene therapies based on proprietary AAV vectors.
Founded
2013
Headquarters
Emeryville, CA, United States
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
No longer available
Total Funding
No longer available
Last Funding Round
No longer available

Learn more about 4D Molecular Therapeutics (4DMT)

To invest in 4D Molecular Therapeutics (4DMT) pre-IPO

Can you invest in 4D Molecular Therapeutics (4DMT) pre-IPO?

You may invest in 4D Molecular Therapeutics (4DMT) as it is a public company listed on the NASDAQ with ticker FDMT. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of 4D Molecular Therapeutics (4DMT) before it goes public?

You can no longer sell shares of 4D Molecular Therapeutics (4DMT) on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my 4D Molecular Therapeutics (4DMT) shares?

Forge can no longer determine the value of 4D Molecular Therapeutics (4DMT) shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is 4D Molecular Therapeutics (4DMT) a publicly traded company?

4D Molecular Therapeutics (4DMT) became a public company following its IPO on 12/11/2020 and is now traded on the NASDAQ under the ticker FDMT.

To learn more about 4D Molecular Therapeutics (4DMT) potential IPO

Will 4D Molecular Therapeutics (4DMT) go IPO?

4D Molecular Therapeutics (4DMT) became a public company following its IPO on 12/11/2020 and is now traded on the NASDAQ under the ticker FDMT.

What is 4D Molecular Therapeutics (4DMT)’s IPO price?

The IPO price of 4D Molecular Therapeutics (4DMT) is not currently available.

When was 4D Molecular Therapeutics (4DMT) founded?

4D Molecular Therapeutics (4DMT) was founded in 2013.

What is 4D Molecular Therapeutics (4DMT) funding to date?

The funding to date for 4D Molecular Therapeutics (4DMT) is not currently available.

4D Molecular Therapeutics (4DMT) pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
Funding Round Details are not yet available for this company.

4D Molecular Therapeutics (4DMT) IPO news and media highlights

Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics

Astellas Pharma has signed a $962m deal with 4D Molecular Therapeutics (4DMT) for rights to use one of 4DMT's gene therapy vectors for treating a rare eye disease. The US genetic medicines company will receive $20m upfront for its R100 vector technology and could receive up to $942.5m in future fees and milestones. Astellas will be responsible for research, development, manufacturing, and commercialisation and has an option to add two more disease targets.

4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy

4D Molecular Therapeutics (4DMT) has achieved alignment with the FDA over a plan to lift a clinical hold on the Phase 1/2 INGLAXA clinical trial involving 4D-310, a treatment for Fabry disease cardiomyopathy. The company has amended the INGLAXA protocol to decrease the risk of atypical hemolytic uremic syndrome (aHUS), and interim clinical data from the trial is expected to be presented in Q1 2024.

Astellas, 4D Molecular Therapeutics Agree to Licensing Deal

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have agreed to a licensing deal that allows Astellas to use 4DMT's intravitreal retinotropic R100 vector. The R100 vector is used for the delivery of genetic payloads in the treatment of retinal diseases. Astellas initially has rights to one genetic target, with the option to include two more for additional fees.

Astellas paves backloaded biobucks deal to test 4DMT's eye disease gene therapy vector

Astellas Pharma has signed a contract to use 4D Molecular Therapeutics’ gene therapy vector for at least one rare eye disease. As part of the deal, 4DMT will receive $20 million upfront, with potential total milestones of $942.5 million. Astellas will use the vector to deliver its own genetic payloads and will be responsible for R&D, manufacturing, and commercialization for the resulting programs. The deal aligns with Astellas' focus on blindness and regeneration as part of its R&D strategy.
Browse More Insights

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61MM$1.62$40MM
OriginOriginNot available$ xx.xxNot available------

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Actively traded

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
Anduril Anduril $111.48 +$0.51 (0.46%)High $xxx.xx
SpaceX SpaceX $601.17 -$0.77 (0.13%)High $xxx.xx
OpenAI OpenAI $728.44 +$0.16 (0.02%)High $xxx.xx
Databricks Databricks $196.29 +$0.09 (0.05%)High $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Anthropic Anthropic $259.14 -$13.84 (5.07%)High $xxx.xx
Anduril Anduril $111.48 +$0.51 (0.46%)High $xxx.xx
OpenAI OpenAI $728.44 +$0.16 (0.02%)High $xxx.xx
Databricks Databricks $196.29 +$0.09 (0.05%)High $xxx.xx
Figure AI Figure AI $174.00 -$20.00 (10.31%)Limited $xxx.xx

Forge, your trusted partner for pre-IPO insights and 4D Molecular Therapeutics (4DMT) data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Jul 16, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.